| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| References | |
|---|---|
| Additional Infomation |
Alkaline phosphatase (AP) is an oral medication with very few side effects. AP acts only locally in the colon, reducing persistent colonic inflammation caused by Gram-negative bacterial endotoxins and extracellular ATP in patients with ulcerative colitis (UC). AP is an enzyme that catalyzes the conversion of orthophosphate monoesters and water into alcohols and orthophosphates. EC 3.1.3.1. Indications: It has been studied for the treatment of ulcerative colitis. Mechanism of Action: Gram-negative bacterial endotoxins (LPS) and adenosine triphosphate (ATP) are two substrates that can disrupt organ homeostasis. Studies have shown that the dephosphorylation of LPS and extracellular ATP by AP can reduce inflammation-induced damage, thereby restoring homeostasis in target organs such as the gastrointestinal tract and kidneys. In the gastrointestinal tract, the main source of LPS is colonized Gram-negative microorganisms. The colonic mucosal surface of patients with ulcerative colitis (UC) is characterized by intermittent damage and increased permeability due to chronic inflammation. The consequences of intestinal mucosal damage include decreased alkaline phosphatase (AP) levels and increased infiltration of LPS-reactive cells, thereby maintaining the inflammatory response. In the gastrointestinal tract, the primary source of LPS is colonized Gram-negative microorganisms. AP alleviates LPS-mediated inflammation by inhibiting intestinal epithelial cell activation and preventing systemic inflammatory responses caused by endotoxin leakage through the inflamed intestinal mucosa with increased permeability.
|
| Exact Mass |
496.275
|
|---|---|
| CAS # |
9001-78-9
|
| PubChem CID |
18985873
|
| Appearance |
White to off-white solid powder
|
| Density |
1.12 g/mL at 20 °C
|
| Boiling Point |
1.41 °C
|
| LogP |
-5
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
35
|
| Complexity |
846
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1CCCN1C(C(C)N)=O)NCC(N1CCCC1C(NC(C(=O)O)CCC/N=C(\N)/N)=O)=O
|
| InChi Key |
ITZMJCSORYKOSI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H36N8O6/c1-12(22)19(33)29-10-4-6-14(29)17(31)26-11-16(30)28-9-3-7-15(28)18(32)27-13(20(34)35)5-2-8-25-21(23)24/h12-15H,2-11,22H2,1H3,(H,26,31)(H,27,32)(H,34,35)(H4,23,24,25)
|
| Chemical Name |
2-[[1-[2-[[1-(2-aminopropanoyl)pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA